OQS
OPRX icon

Occudo Quantitative Strategies’s OptimizeRx OPRX Stock Holding History

Occudo Quantitative Strategies’s Portfolio OPRX Stock Details OPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-19,967
Closed -$286K – 959
2023
Q4 		$286K Buy
+19,967
New +$192K 0.04% 550

Other funds holding OPRX

FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
DSCM
Divisadero Street Capital Management Miami, Florida $2.39B AUM 134.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
SM
Samjo Management New York $231M AUM 13.04% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GIPM
G2 Investment Partners Management New York $406M AUM 164.47% 1-Year Est. Return

Occudo Quantitative Strategies's OPRX Position: Q1 2024 in Review

Occudo Quantitative Strategies sold out of OptimizeRx (OPRX) in Q1 2024, closing a stake of 19,967 shares — an estimated $286K sold.

Occudo Quantitative Strategies first reported a position in OPRX in Q4 2023 and held it in 1 quarter. The position peaked at $286K in Q4 2023. 97 funds tracked by Wall St. Rank hold OPRX as of Q1 2024.

  • Occudo Quantitative Strategies reported no remaining OptimizeRx position as of Q1 2024 after selling out during the quarter.
  • Occudo Quantitative Strategies sold 19,967 OptimizeRx shares in Q1 2024, an estimated $286K.
  • Occudo Quantitative Strategies first reported a position in OptimizeRx in Q4 2023 and held it in 1 quarter.
  • Occudo Quantitative Strategies's OptimizeRx position peaked at $286K in Q4 2023.
  • 97 funds tracked by Wall St. Rank held OptimizeRx as of Q1 2024.

Based on Occudo Quantitative Strategies's 13F filing for Q1 2024, filed 15 May 2024.